KalVista Pharmaceuticals, Inc. (KALV)
2025-07-31 | 2024-10-31 | |||
|---|---|---|---|---|
| Product revenue, net | 1,426 | - | ||
| General and administrative expense, total | - | 29,201 | ||
| Selling, general and administrative | 44,683 | - | ||
| Research and development | 15,162 | 16,610 | ||
| Cost of revenue | 590 | - | ||
| Total operating expenses | 60,435 | 45,811 | ||
| Operating loss | -59,009 | -45,811 | ||
| Other income | 818 | 2,119 | ||
| Interest income | 1,849 | 1,357 | ||
| Interest (expense) | 3,522 | - | ||
| Foreign currency exchange gain | 1,925 | 67 | ||
| Total other income | 1,070 | 3,543 | ||
| Loss before income taxes | -57,939 | - | ||
| Income tax expense | 2,157 | - | ||
| Net loss | -60,096 | -42,268 | ||
| Unrealized holding gain on marketable securities | 18 | 651 | ||
| Reclassification adjustment for realized gain on marketable securities included in net loss | 587 | 649 | ||
| Foreign currency translation loss | -604 | 166 | ||
| Total other comprehensive (loss) income | -1,173 | 168 | ||
| Comprehensive loss | -61,269 | -42,100 | ||
| Earnings per share, basic | -1.12 | -0.91 | ||
| Earnings per share, diluted | -1.12 | -0.91 | ||
| Weighted average common shares outstanding, basic | 53,497,128 | 46,695,220 | ||
| Weighted average common shares outstanding, diluted | 53,497,128 | 46,695,220 | ||